Why the study?
Do specific immune-dominant epitopes of cTni function effectively as competitors in an indirect competitive ELISA for cTni detection?
Do specific immune-dominant epitopes of cTni function effectively as competitors in an indirect competitive ELISA for cTni detection?
Two specific immune-dominant epitopes of cardiac troponin I demonstrated significant sensitivity and inhibition ability when used as competitors in a novel indirect competitive ELISA.
Supports epitope-based cTnI ELISA development; hypothesis-generating for clinical translation pending human validation.
Human cardiac troponin I (cTni) is the gold marker for early diagnosis of myocardial infarction. In this regard, four immune-dominant epitopes of cTni were predicted and their 3D structures were determined. Thereafter, the competitive performance of the peptides was monitored with the developed polyclonal antibody-based indirect competitive ELISA; a half-maximal inhibitory concentration (IC50) of 0.49 (µg/mL) and detection limit of 0.037 (µg/mL) were achieved for recombinant cTni. The competitive ELISA determined sensitivity levels of 0.306, 0.141, 0.960, and 0.155 (µg/mL), respectively, for each peptide as competitor. We indicated that two of the selected epitopes have significant sensitivity scales and inhibition ability.
No takes yet. Share an insight, caveat, or question.
Rezaee et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: